The field of gene editing recently got a major boost from Massachusetts-based Beam Therapeutics, and the company’s Durham ...

United Therapeutics has high revenue growth and low debt. Read why UTHR stock is undervalued with solid financial metrics and ...

United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $735.90 million for the quarter, compared to analyst estimates of $734.74 million.

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., March 04, 2025--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that ...

United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company had revenue of $735.90 million for the quarter, compared to the consensus estimate of $734.74 million.

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life ...

Under the Trump administration, the EPA is reportedly considering plans to dissolve its scientific research office. At ...

Investors in United Therapeutics Corp (Symbol: UTHR) saw new options become available this week, for the November 21st expiration. One of the key inputs that goes into the price an option buyer is ...

Mary Helen Moore is a reporter with the NC Newsroom, a journalism collaboration expanding state government news coverage for ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...